14156-95-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-METHYL-PIPERIDIN-1-YL)-ETHYLAMINE is used as a key intermediate for the synthesis of various pharmaceuticals and research chemicals. Its unique structure allows for the creation of a wide range of compounds with diverse therapeutic properties.
Used in Organic Compound Production:
In the chemical industry, 2-(4-METHYL-PIPERIDIN-1-YL)-ETHYLAMINE is used as a building block for the production of various organic compounds. Its versatility in chemical reactions makes it a valuable component in the synthesis of heterocycles and other complex organic molecules.
Used in Drug Development:
2-(4-METHYL-PIPERIDIN-1-YL)-ETHYLAMINE is utilized in drug development as a precursor for the creation of new drug candidates. Its ability to form stable bonds with other molecules makes it an essential component in the development of innovative pharmaceuticals with potential therapeutic applications.
Used in Research and Development:
In the field of research and development, 2-(4-METHYL-PIPERIDIN-1-YL)-ETHYLAMINE is employed as a reagent for studying the properties and reactions of various chemical compounds. Its unique structure and reactivity make it a valuable tool for understanding the behavior of different organic molecules and their potential applications.
Used in Chemical Intermediates:
2-(4-METHYL-PIPERIDIN-1-YL)-ETHYLAMINE is used as a chemical intermediate in the production of various compounds. Its ability to participate in a wide range of chemical reactions makes it a crucial component in the synthesis of numerous organic and inorganic compounds.

InChI:InChI=1/C8H18N2/c1-8-2-5-10(6-3-8)7-4-9/h8H,2-7,9H2,1H3

Upstream product

• 626-58-4 4-methylpiperidin 
• 689300-49-0 tert-butyl (2-(4-methylpiperidin-1-yl)ethyl)carbamate 
• 847574-01-0 (4-methyl-piperidin-1-yl)-acetonitrile 

Downstream Products

• 866930-24-7 (4-bromo-2-methyl-phenyl)-[2-(4-methyl-piperidin-1-yl)-ethyl]-amine 
• 847573-84-6 N-(6,7-methylenedioxyquinolin-4-yl)-N-[2-(4-methylpiperidin-1-yl)ethyl]-2-iodo-4,5-dimethoxybenzamide 

Relevant academic research and scientific papers

N-Aryl-N’-ethyleneaminothioureas effectively inhibit acetylcholinesterase 1 from disease-transmitting mosquitoes

Vector control of disease-transmitting mosquitoes by insecticides has a central role in reducing the number of parasitic- and viral infection cases. The currently used insecticides are efficient, but safety concerns and the development of insecticide-resistant mosquito strains warrant the search for alternative compound classes for vector control. Here, we have designed and synthesized thiourea-based compounds as non-covalent inhibitors of acetylcholinesterase 1 (AChE1) from the mosquitoes Anopheles gambiae (An. gambiae) and Aedes aegypti (Ae. aegypti), as well as a naturally occurring resistant-conferring mutant. The N-aryl-N’-ethyleneaminothioureas proved to be inhibitors of AChE1; the most efficient one showed submicromolar potency. Importantly, the inhibitors exhibited selectivity over the human AChE (hAChE), which is desirable for new insecticides. The structure-activity relationship (SAR) analysis of the thioureas revealed that small changes in the chemical structure had a large effect on inhibition capacity. The thioureas showed to have different SAR when inhibiting AChE1 and hAChE, respectively, enabling an investigation of structure-selectivity relationships. Furthermore, insecticidal activity was demonstrated using adult and larvae An. gambiae and Ae. aegypti mosquitoes.

5-(2-Aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: Variation of N-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance

5H-8,9-Dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenedioxydibenzo[c, h]-[1,6]naphthyridin-6-one (ARC-111) has potent TOP1-targeting activity and pronounced antitumor activity. Several analogues of ARC-111 were synthesized with NH2, N-alkyl, N,N-dialkyl, pyrrolidinyl, piperidinyl, and piperazinyl substituents at the 2-position of the 5-ethyl group. The relative TOP1-targeting activity and cytotoxicity of these structural analogues were assessed in RPMI8402 and P388 tumor cells and their camptothecin-resistant variants CPT-K5 and P388/CPT45, respectively. Potent TOP1-targeting activity was retained within a series of mono N-alkyl analogues that included NHCH 2CH3, NHCH(CH3)2, and NHC(CH 3)3. TOP1-targeting activity was diminished by the presence of a N-benzyl moiety. In a comparison of a series of N-alkyl-N-isopropyl analogues, activity decreased in the order CH3 > CH2CH3 > CH-(CH3)2. Cytotoxicity in RPMI8402 and P388 did correlate with TOP1-targeting activity. Cytotoxic activity was also determined in KB3-1 cells and its variants KB/V-1 and KBH5.0. As KB/V-1 cells overexpress MDR1 and KBH5.0 cells overexpress BCRP, decreased cytotoxicity in these cell lines relative to the parent cell line is indicative of compounds that are substrates for these efflux transporters. In view of their diminished cytotoxicity in KB/V-1 cells, it appears that the likely demethylated metabolites of ARC-111, i.e., where NH2 or NHCH3 replaces the N(CH3)2 at the 2-position of the 5-ethyl substituent, are substrates for MDR1. In contrast, no significant difference in cytotoxicity among these three cell lines was observed with other N-alkyl analogues, including NHC2H5, NHCH(CH 3)2, NHC(CH3)3, N(CH 3)2, N(CH2CH3)2, NCH 3(CH-(CH3)2), and either the pyrrolidinyl or the piperidinyl analogues. The 2-(piperazinyl) analogues were associated with diminished cytotoxicity in KB/V-1 cells, suggesting that the second basic amino substituent is associated with their recognition as substrates by MDR1. Comparative studies on the antitumor activity of ARC-111 and its N-demethylated derivatives (the NHCH3 and NH2 analogues) against SJ-BT45 medulloblastoma xenografts in seid mice revealed that the secondary amine metabolite is at least as active as ARC-111 in vivo, although the primary amine derivative was significantly less potent.